New Terrain fully understand the huge risk of new drug development. For new drug approval, we follow the principles of “Safety, Effective and Quality assurance” as well as the strict specifications for experiments of drug development. In order to help customers, shorten the development time cycle and lower cost, we undertake Contract Research Organization service (CRO) for diseases mechanism research and drug development. We are committed to consulting and technical services to assist clients implement new drug development projects quickly and efficiently.
We have rich experience in neurological drug development services. We also have experiences in drug development and evaluation of small molecule compounds, and biological macromolecules. We are able to provide single project services and packaged comprehensive project services in chemistry, biology, pharmacology, pharmacokinetics etc. Moreover, we provide medical project outsourcing services, covering a series of scientific research projects related processes from project consultation, program design and optimization, experimental development, to experimental data analysis and publication.
Our clinical trial services include clinical trial technical services and clinical trial related services related to neurological diseases.
Disease | Druges | Target | Sponsor | Stage | Chinese PI |
---|---|---|---|---|---|
Multiple sclerosis | Fenebruntinib | BTK inhibitor | Roche | III | Fu-Dong Shi |
Ofatumumab | CD20 | Novartis | IV | Fu-Dong Shi | |
Diroximel Fumarate | DHODH | Biogen | IV | Fu-Dong Shi | |
Orelabrutinib | BTK inhibitor | InnoCare | II | Liying Cui | |
SAR442168 (Tolebrutinib) | BTK inhibitor | Sanofi | III | Liying Cui | |
SAR442168 (Tolebrutinib) | BTK inhibitor | Sanofi | III | Qiang Dong | |
Myasthenia gravis | Inebilizumab | CD19 | Viela Bio | III | Fu-Dong Shi |
Satralizumab | IL-6 receptor | Roche | III | Chongbo Zhao | |
Nipocalimab | FcRn-IgG | Johnson & Johnson | III | Huan Yang | |
Batoclimab | FcRn-IgG | Harbour BioMed | II-III | Chongbo Zhao | |
NMO | B001 | CD20 | Shanghai Pharma | Ib | Fu-Dong Shi |
MOGAD | Satralizumab | IL-6 receptor | Roche | III | Fu-Dong Shi |
Rozanolixizumab | FcRn-IgG | UCB | III | Fu-Dong Shi | |
AE(Lgl-1) | Rozanolixizumab | FcRn-IgG | UCB | II | Fu-Dong Shi |
AIS | Xianbixin | —— | Simcere | PMS | Fu-Dong Shi |
Butyphthalide | —— | CSPC PHARMA | PMS | Fu-Dong Shi |